2026-01-10 - Analysis Report
Okay, here's a breakdown and analysis of Teladoc Health (TDOC) based on the provided data.

**1. Return Rate Comparison**

*   **Company Overview:** Teladoc Health Inc. is a telehealth company providing virtual healthcare services.
*   **TDOC Cumulative Return:** -61.74%
*   **S&P 500 (VOO) Cumulative Return:** 92.74%
*   **Divergence:** -155.5 (Relative Divergence: 0.7)

**Analysis:**

TDOC has significantly underperformed the S&P 500. The large negative cumulative return and the highly negative divergence figures indicate a substantial and prolonged period of underperformance compared to the broader market. The relative divergence of 0.7 suggests the current underperformance is near the lower end of its historical range, however, it is still strongly negative.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha    | Beta   | Cap(B) |
|------------|---------|---------|----------|--------|--------|
| 2016-2018  | 74.0%   | 52.9%   | 71.0%    | 1.7    | 8.6    |
| 2017-2019  | 119.0%  | 52.9%   | 101.0%   | 1.8    | 14.6   |
| 2018-2020  | 87.0%   | 52.9%   | 66.0%    | 0.7    | 34.8   |
| 2019-2021  | -84.0%  | 60.6%   | -127.0%  | 0.5    | 16.0   |
| 2020-2022  | -246.0% | 83.0%   | -244.0%  | 0.8    | 4.1    |
| 2021-2023  | -302.0% | 83.0%   | -303.0%  | 1.9    | 3.8    |
| 2022-2024  | -87.0%  | 72.3%   | -107.0%  | 1.9    | 1.6    |
| 2023-2025  | -34.0%  | 65.6%   | -96.0%   | 1.7    | 1.2    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows strong positive growth in the early periods, but this has deteriorated significantly in recent years, showing deeply negative returns.
*   **MDD:** The Maximum Drawdown indicates substantial risk, with drawdowns consistently high.
*   **Alpha:**  Alpha is overwhelmingly negative in recent years, indicating significant underperformance relative to the market.
*   **Beta:** Beta fluctuates, suggesting the stock's volatility relative to the market changes over time. In recent years, Beta has been higher, indicating more volatility than the market.
*   **Cap(B):** The market capitalization has declined in recent years, which coincides with negative performance

**2. Stock Price Fluctuations**

*   **Current Close:** 7.61
*   **Last Market Data:** Price: 7.46, Previous Close: 7.61, Change: -1.97%
*   **5-day SMA:** 7.50
*   **20-day SMA:** 7.33
*   **60-day SMA:** 7.70

**Analysis:**

The price closed lower than the previous close. The 5-day SMA is above the 20-day SMA, suggesting a short-term upward trend.  However, both are below the 60-day SMA, indicating the longer-term trend is still down.

**3. Index Indicators**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 58.26
*   **PPO:** 1.00
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.70)
*   **Recent Divergence Change:** 0.7 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** -9726.1 (Very negative excess return)

**Analysis:**

*   The MRI suggests a medium investment risk level.
*   The RSI is close to the overbought level.
*   A positive PPO shows an upward momentum.
*   The hybrid signal is suggesting to buy 80% of cash, implying caution.
*   The short-term increase in relative divergence change is positive.
*   However, the expected return is massively negative, indicating a very high risk if holding the stock long term.

**4. Recent News & Significant Events**

*   **Analyst Target Price Cut:** Citigroup lowered the target price.
*   **Risk-Controlled Trading Report:** Indicates active monitoring of risk.
*   **Comparison to HIMS:** Highlights competition in the telehealth space.
*   **Losing Its Edge?** Concerns about competition from BetterHelp and other virtual care providers.
*   **Healthcare Stock Alternative:** Suggests other potentially better investment options.
*   **Reasons to Forget TDOC:** Indicates negative sentiment.

**Analysis:**

Recent news sentiment is largely negative.  Analysts are lowering targets, competition is increasing, and some articles suggest investors should look elsewhere. This negative news flow is likely contributing to downward pressure on the stock price.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (Mean: 2.67)
*   **Target Price:** $9.06 (Avg), $12.00 (High), $7.00 (Low)

**Analysis:**

The analyst consensus is a "Hold" with a target price significantly above the current price. This suggests analysts believe the stock is undervalued, but not enough to warrant a "Buy" rating. However, the recent target price cut should be concerning.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-10-30 | -0.28 | 0.63 B$      |
| 2025-07-30 | -0.19 | 0.63 B$      |
| 2025-05-01 | -0.53 | 0.63 B$      |
| 2024-10-31 | -0.19 | 0.64 B$      |
| 2025-10-30 | -0.19 | 0.64 B$      |

**Analysis:**

The company is consistently reporting negative EPS, indicating unprofitability. Revenue is relatively stable, but not growing significantly. This is a major concern for investors.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.63B   | 70.12%        |
| 2025-06-30 | $0.63B   | 69.85%        |
| 2025-03-31 | $0.63B   | 68.73%        |
| 2024-12-31 | $0.64B   | 70.50%        |
| 2024-09-30 | $0.64B   | 71.94%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-09-30 | $1.39B   | -3.56% |
| 2025-06-30 | $1.42B   | -2.30% |
| 2025-03-31 | $1.43B   | -6.52% |
| 2024-12-31 | $1.49B   | -3.25% |
| 2024-09-30 | $1.51B   | -2.21% |

**Analysis:**

Revenue is relatively stable, but not showing significant growth. Profit margins are good. The Return on Equity (ROE) is negative, reinforcing the unprofitability indicated by the negative EPS. Equity is also declining.

**7. Comprehensive Analysis (Summary)**

Teladoc Health (TDOC) is currently facing significant challenges. It has dramatically underperformed the S&P 500, is reporting consistent losses (negative EPS and ROE), and faces increasing competition in the telehealth market. While the stock shows a short-term upside potential and a 'Hold' rating from analysts, the largely negative news flow and the large negative expected returns suggest caution.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.